{
  "id": "Ex093",
  "type": "Example",
  "informationId": {
    "id": "CG-EX:CritAssess374",
    "type": "CriterionAssessment",
    "criterion": {
      "id": "Crit306",
      "type": "Criterion",
      "description": "Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product",
      "comments": "This particular rule will probably be downgraded often, given that there are not many “Functional studies that have been validated and shown to be reproducible and robust in a clinical diagnostic laboratory setting”",
      "defaultStrength": {
        "id": "SEPIO:0000330",
        "label": "Pathogenic Strong"
      },
      "label": "PS3"
    },
    "variant": {
      "id": "CAR:CA090930",
      "type": "CanonicalAllele",
      "preferredCtxAllele": {
        "id": "CG-EX:CtxAll130",
        "type": "ContextualAllele",
        "relatedCanonicalAllele": "CAR:CA090930",
        "alleleName": "NM_005633.3(SOS1):c.1010A>G (p.Tyr337Cys)"
      }
    },
    "outcome": {
      "id": "SEPIO:0000223",
      "label": "Met"
    },
    "evidenceLine": [
      {
        "id": "CG-EX:EvLn116",
        "type": "EvidenceLine",
        "evidenceItem": [
          {
            "id": "CG-EX:Func067",
            "type": "AlleleFunctionalImpact",
            "resultDescription": "increased ERK activtation",
            "assayType": {
              "id": "AFAMID076",
              "label": "Activation Assay"
            },
            "contextualAllele": {
              "id": "CG-EX:CtxAll130",
              "type": "ContextualAllele",
              "relatedCanonicalAllele": "CAR:CA090930",
              "alleleName": "NM_005633.3(SOS1):c.1010A>G (p.Tyr337Cys)"
            },
            "gene": {
              "id": "HGNC:11187",
              "label": "SOS1"
            },
            "description": "PMID: 23487764"
          }
        ]
      }
    ],
    "contribution": [
      {
        "type": "Contribution",
        "agent": {
          "id": "CG-EX:Agent007",
          "type": "Agent",
          "label": "Stefan DiMarino"
        },
        "contributionDate": "3/14/2017 10:29 AM",
        "contributionRole": {
          "id": "SEPIO:0000154",
          "label": "assessor role"
        }
      }
    ],
    "description": "Flag-tagged construct with the variant was transfected into HEK cells. As per the RASopathy working group’s approved assays (see example 3 above), Smith et al. showed that the Y337C mutation increased levels of pERK in starved HEK cells via western blotting."
  },
  "index": 4,
  "author": "Marina DiStefano",
  "description": "Assessed Variant: NM_005633.3(SOS1):c.1010A>G (p.Tyr337Cys)\nPMID: 23487764\n\nA Flag-tagged construct with the variant was transfected into HEK cells. As per the RASopathy working group’s approved assays (see example 3 above), Smith et al. showed that the Y337C mutation increased levels of pERK in starved HEK cells via western blotting. Thus, PP4 can be applied.",
  "@context": "http://datamodel.clinicalgenome.org/interpretation/json/context"
}
